ArticleCase reports in neurological medicine2026
Botulinum Toxin A in Poststroke Oromandibular Dystonia: Case Reports.
Article in Case reports in neurological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Botulinum Toxin A in Poststroke Oromandibular Dystonia: Case Reports.Case reports in neurological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Poststroke oromandibular dystonia (OMD) is a rare and challenging to treat form of dystonia. Botulinum toxin A (BoNT-A) is a standard treatment in other etiologies of OMD, but literature concerning a long-term potential beneficial role in posthemorrhagic stroke OMD is scarce. Cases: We present a case series of three patients with acute onset of multiple cranial nerve impairment and contralateral hemiparesis consequent to pontine hemorrhage. After a few months, all patients developed jaw-closing OMD (JC-OMD), conditioning a reduced mouth opening. Ultrasound-guided BoNT-A administration was started, and after 4 weeks, every patient showed clinical improvement. The results were maintained up to 10 years of follow-up, and no adverse event was reported. Conclusions: Poststroke OMD is an underestimated condition. Our cases provided data of safety and efficacy of BoNT-A treatment up to 10 years of follow-up. Further studies are warranted to establish etiopathological mechanisms and standardized treatments for poststroke JC-OMD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.